Open AccessA Randomized, Double-Blind Placebo Controlled Trial of Balapiravir, a Polymerase Inhibitor, in Adult Dengue Patients
Author(s) -
Nguyet Minh Nguyen,
Chau Nguyen Tran,
Phung Khanh Lam,
Kien Thi Hue Duong,
Huy Huynh,
Jeremy Farrar,
Quyen Than Ha Nguyen,
Hien Tinh Tran,
Nguyễn Văn Vĩnh Châu,
Laura Merson,
Long Hoàng,
Martin L. Hibberd,
Pauline Aw,
Andreas Wilm,
Niranjan Nagarajan,
Dung Thi Nguyen,
Phạm Phương,
Truong Thanh Nguyen,
Hassan Javanbakht,
Klaus Klumpp,
Janet Hammond,
Rosemary Petric,
Marcel Wolbers,
Chinh Tran Nguyen,
Cameron P. Simmons
Publication year - 2012
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jis470
Subject(s) - dengue fever , dengue virus , placebo , medicine , viremia , adverse effect , pharmacokinetics , pharmacology , potency , clinical trial , pharmacodynamics , immunology , randomized controlled trial , virology , gastroenterology , virus , biology , in vitro , pathology , alternative medicine , biochemistry
Dengue is the most common arboviral infection of humans. There are currently no specific treatments for dengue. Balapiravir is a prodrug of a nucleoside analogue (called R1479) and an inhibitor of hepatitis C virus replication in vivo.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom